Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Genetic Variation in PDCD6 and Susceptibility to Lung Cancer

  • He, Yan-Qi (Department of Respiratory Medicine, West China Hospital of Sichuan University) ;
  • Zhou, Bin (Laboratory of Molecular Translational Medicine, West China Second University Hospital) ;
  • Shi, Shao-Qing (Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University) ;
  • Zhang, Lin (Laboratory of Molecular Translational Medicine, West China Second University Hospital) ;
  • Li, Wei-Min (Department of Respiratory Medicine, West China Hospital of Sichuan University)
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Lung cancer is the most common type of cancer and one of the leading causes of death in the world. Genetic factors play an important role in its development. PDCD6, the encoding gene for programmed cell death protein 6, may function as a tumor suppressor gene. Non-small cell lung cancer (NSCLC) contributes about 80% to newly histologically diagnosed lung cancer patients. To explore the relationship between PDCD6 and NSCLC, we examined two single nucleotide polymorphisms(rs3756712 G/T andrs4957014 G/T, both in the intron region) of the PDCD6gene.A hospital-based case-control study was carried out including 302 unrelated NSCLC patients and 306 healthy unrelated subjects. Significantly increased NSCLC risk was found to be associated with the T allele of rs4957014 (P=0.027, OR=0.760, 95%CI=0.596-0.970). The genotype and allele frequencies of rs3756712 did not shown any significant difference between NSCLC group and controls (P=0.327, OR=0.879, 95%CI=0.679-1.137). In conclusion, we firstly demonstrated the association between the PDCD6 gene and risk of NSCLC in a Chinese Han population.

Keywords

References

  1. Amos CI, Caporaso NE, Weston A (1992). Host factors in lung cancer risk: a review of interdisciplinary studies. Cancer Epidemiol Biomarkers Prev, 1, 505-13.
  2. Chatellard-Causse C, Blot B, Cristina N, et al (2002). Alix (ALG- 2-interacting protein X), a protein involved in apoptosis, binds to endophilins and induces cytoplasmic vacuolization. J Biol Chem, 277, 29108-15. https://doi.org/10.1074/jbc.M204019200
  3. Chen C, Sytkowski AJ (2005). Apoptosis-linked gene-2 connects the Raf-1 and ASK1 signalings. Biochem Biophys Res Commun, 333, 51-7. https://doi.org/10.1016/j.bbrc.2005.05.074
  4. Chen YC, Peng GS, Wang MF, Tsao TP, Yin SJ (2009). Polymorphism of ethanol-metabolism genes and alcoholism: correlation of allelic variations with the pharmacokinetic and pharmacodynamic consequences. Chem Biol Interact, 178, 2-7. https://doi.org/10.1016/j.cbi.2008.10.029
  5. Dai M, Ren JS, Li N, Li Q, Yang L, Chen YH (2012). [Estimation and prediction on cancer related incidence and mortality in China, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi, 33, 57-61.
  6. Dhar S, Squire JA, Hande MP, Wellinger RJ, Pandita TK (2000). Inactivation of 14-3-3sigma influences telomere behavior and ionizing radiation-induced chromosomal instability. Mol Cell Biol, 20, 7764-72. https://doi.org/10.1128/MCB.20.20.7764-7772.2000
  7. Dogu GG, Kargi A, Turgut S, et al (2012). MDR1 single nucleotide polymorphism C3435T in Turkish patients with non-small-cell lung cancer. Gene, 506, 404-7 https://doi.org/10.1016/j.gene.2012.06.057
  8. Draeby I, Woods YL, la Cour JM, et al (2007). The calcium binding protein ALG-2 binds and stabilizes Scotin, a p53-inducible gene product localized at the endoplasmic reticulum membrane. Arch Biochem Biophys, 467, 87-94. https://doi.org/10.1016/j.abb.2007.07.028
  9. Felip E, Stahel RA, Pavlidis N (2005). ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol, 16, i28-9. https://doi.org/10.1093/annonc/mdi821
  10. Fine A, Janssen-Heininger Y, Soultanakis RP, Swisher SG, Uhal BD (2000). Apoptosis in lung pathophysiology. Am J Physiol Lung Cell Mol Physiol, 279, L423-7.
  11. Gu S, Wu Q, Zhao X, et al (2012). Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy. Cancer Sci, 103, 1451-9 https://doi.org/10.1111/j.1349-7006.2012.02323.x
  12. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T et al (1997). Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science, 275, 90-4. https://doi.org/10.1126/science.275.5296.90
  13. Jemal A, Bray F, Center MM, et al (2011). CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  14. Jung YS, Kim KS, Kim KD, et al (2001). Apoptosis-linked gene 2 binds to the death domain of Fas and dissociates from Fas during Fas-mediated apoptosis in Jurkat cells. Biochem Biophys Res Commun, 288, 420-6. https://doi.org/10.1006/bbrc.2001.5769
  15. Katoh K, Suzuki H, Terasawa Y, et al (2005). The penta-EFhand protein ALG-2 interacts directly with the ESCRT-I component TSG101, and Ca2+-dependently co-localizes to aberrant endosomes with dominant-negative AAA ATPase SKD1/Vps4B. Biochem J, 391, 677-85. https://doi.org/10.1042/BJ20050398
  16. Krempler A, Henry MD, Triplett AA, Wagner KU (2002). Targeted deletion of the Tsg101 gene results in cell cycle arrest at G1/S and p53-independent cell death. J Biol Chem, 277, 43216-23. https://doi.org/10.1074/jbc.M207662200
  17. Kutikhin AG (2011). Role of NOD1/CARD4 and NOD2/ CARD15 gene polymorphisms in cancer etiology. Hum Immunol, 72, 955-68. https://doi.org/10.1016/j.humimm.2011.06.003
  18. la Cour JM, Mollerup J, Winding P, Tarabykina S, Sehested M, Berchtold MW (2003). Up-regulation of ALG-2 in hepatomas and lung cancer tissue. Am J Pathol, 163, 81-9. https://doi.org/10.1016/S0002-9440(10)63632-2
  19. la Cour JM, Mollerup J, Berchtold MW (2007). ALG-2 oscillates in subcellular localization, unitemporally with calcium oscillations. Biochem Biophys Res Commun, 353, 1063-7. https://doi.org/10.1016/j.bbrc.2006.12.143
  20. la Cour JM, Hoj BR, Mollerup J, et al (2008). The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Mol Oncol, 1, 431-9. https://doi.org/10.1016/j.molonc.2007.08.002
  21. Lissowska J, Foretova L, Dabek J, et al (2010). Family history and lung cancer risk: international multicentre case-control study in Eastern and Central Europe and meta-analyses. Cancer Causes Control, 21, 1091-104. https://doi.org/10.1007/s10552-010-9537-2
  22. Mahul-Mellier AL, Hemming FJ, Blot B, Fraboulet S, Sadoul R (2006). Alix, making a link between apoptosis-linked gene-2, the endosomal sorting complexes required for transport, and neuronal death in vivo. J Neurosci, 26, 542-9. https://doi.org/10.1523/JNEUROSCI.3069-05.2006
  23. McGrath EE (2011). The tumor necrosis factor-related apoptosisinducing ligand and lung cancer: still following the right TRAIL? J Thorac Oncol, 6, 983-7. https://doi.org/10.1097/JTO.0b013e318217b6c8
  24. Missotten M, Nichols A, Rieger K, Sadoul R (1999). Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Cell Death Differ, 6, 124-9. https://doi.org/10.1038/sj.cdd.4400456
  25. Miyashita T, Reed JC (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80, 293-9. https://doi.org/10.1016/0092-8674(95)90412-3
  26. Nakada T, Kiyotani K, Iwano S, et al (2012). Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway. J Toxicol Sci, 37, 555-63. https://doi.org/10.2131/jts.37.555
  27. Oda E, Ohki R, Murasawa H, et al (2000a). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53- induced apoptosis. Science, 288, 1053-8. https://doi.org/10.1126/science.288.5468.1053
  28. Oda K, Arakawa H, Tanaka T, et al (2000b). p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell, 102, 849-62. https://doi.org/10.1016/S0092-8674(00)00073-8
  29. Osada H, Takahashi T (2002). Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene, 21, 7421-34. https://doi.org/10.1038/sj.onc.1205802
  30. Renehan AG, Booth C, Potten CS (2001). What is apoptosis, and why is it important? BMJ, 322, 1536-8. https://doi.org/10.1136/bmj.322.7301.1536
  31. Rual JF, Venkatesan K, Hao T, et al (2005). Towards a proteomescale map of the human protein-protein interaction network. Nature, 437, 1173-8. https://doi.org/10.1038/nature04209
  32. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P (2008). The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol, 3, 457-66. https://doi.org/10.1097/JTO.0b013e31816de2b8
  33. Shih JY, Yang PC (2011). The EMT regulator slug and lung carcinogenesis. Carcinogenesis, 32, 1299-304. https://doi.org/10.1093/carcin/bgr110
  34. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF (2003). Apoptosis and lung cancer: a review. J Cell Biochem, 88, 885-98. https://doi.org/10.1002/jcb.10440
  35. Spitz MR, Hong WK, Amos CI, et al (2007). A risk model for prediction of lung cancer. J Natl Cancer Inst, 99, 715-26. https://doi.org/10.1093/jnci/djk153
  36. Subramanian L, Polans AS (2004). Cancer-related diseases of the eye: the role of calcium and calcium-binding proteins. Biochem Biophys Res Commun, 322, 1153-65. https://doi.org/10.1016/j.bbrc.2004.07.109
  37. Tarabykina S, Mollerup J, Winding P, Berchtold MW (2004). ALG-2, a multifunctional calcium binding protein? Front Biosci, 9, 1817-32. https://doi.org/10.2741/1358
  38. Tomsig JL, Snyder SL, Creutz CE (2003). Identification of targets for calcium signaling through the copine family of proteins. Characterization of a coiled-coil copine-binding motif. J Biol Chem, 278, 10048-54. https://doi.org/10.1074/jbc.M212632200
  39. Venot C, Maratrat M, Dureuil C, et al (1998). The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J, 17, 4668-79. https://doi.org/10.1093/emboj/17.16.4668
  40. Vito P, Pellegrini L, Guiet C, D'Adamio L (1999). Cloning of AIP1, a novel protein that associates with the apoptosislinked gene ALG-2 in a Ca2+-dependent reaction. J Biol Chem, 274, 1533-40. https://doi.org/10.1074/jbc.274.3.1533
  41. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK et al (2011). Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol, 28, 315-21. https://doi.org/10.1007/s12032-010-9443-1
  42. Xu W, Jiang S, Xu Y, Chen B, Li Y, Zong F et al (2012). A metaanalysis of caspase 9 polymorphisms in promoter and exon sequence on cancer susceptibility. PloS One, 7, e37443. https://doi.org/10.1371/journal.pone.0037443
  43. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B (2001). PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell, xs, 673-82.

Cited by

  1. Prognostic value of PDCD6 polymorphisms and the susceptibility to bladder cancer vol.35, pp.8, 2014, https://doi.org/10.1007/s13277-014-2010-1
  2. Pharmacophore Development for Anti-Lung Cancer Drugs vol.16, pp.18, 2015, https://doi.org/10.7314/APJCP.2015.16.18.8307